Skip to contentA
Anika Therapeutics, Inc.
A
ANIKAnika Therapeutics, Inc. Q3 2020 · 10-Q
Revenue$31.69M$31.69M+6.7% vs Q3 2019 Net Income-$6.41M-$6.41MN/M vs Q3 2019 EPS Diluted-$0.45-$0.45N/M vs Q3 2019 Gross Profit$17,343,000−27.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR
Operating Cash Flowderived$5,865,000−41.6% Free Cash Flowderived$5,594,000−41.9% Margins · derivedGross margin54.7%−25.2 pt vs Q3 2019
Operating margin-25.0%−65.6 pt vs Q3 2019
Net margin-20.2%−51.2 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 5, 2020 · 36 d after period end